News | December 07, 2025
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
Subscribe To Our Newsletter & Stay Updated
